Frontiers in Nutrition (Dec 2023)

Blood lipids, lipid-regulatory medications, and risk of bladder cancer: a Mendelian randomization study

  • Zhang Cheng,
  • Zhang Cheng,
  • Fangdie Ye,
  • Fangdie Ye,
  • Yingchun Liang,
  • Yingchun Liang,
  • Chenyang Xu,
  • Chenyang Xu,
  • Zheyu Zhang,
  • Zheyu Zhang,
  • Yuxi Ou,
  • Yuxi Ou,
  • Xinan Chen,
  • Xinan Chen,
  • Xiyu Dai,
  • Xiyu Dai,
  • Zezhong Mou,
  • Zezhong Mou,
  • Weijian Li,
  • Weijian Li,
  • Yiling Chen,
  • Yiling Chen,
  • Quan Zhou,
  • Quan Zhou,
  • Lujia Zou,
  • Lujia Zou,
  • Shanhua Mao,
  • Shanhua Mao,
  • Haowen Jiang,
  • Haowen Jiang,
  • Haowen Jiang

DOI
https://doi.org/10.3389/fnut.2023.992608
Journal volume & issue
Vol. 10

Abstract

Read online

BackgroundThe influences of blood lipids and lipid-regulatory medications on the risk of bladder cancer have long been suspected, and previous findings remain controversial. We aimed to assess the causality between blood lipids or lipid-regulatory medications and bladder cancer susceptibility by means of a comprehensive Mendelian Randomization (MR) study.MethodsGenetic proxies from genome-wide association studies (GWAS) of four blood lipid traits and lipid-lowering variants in genes encoding the targets of lipid-regulatory medications were employed. The largest ever GWAS data of blood lipids and bladder cancer involving up to 440,546 and 205,771 individuals of European ancestry were extracted from UK Biobank and FinnGen Project Round 6, respectively. A two-sample bidirectional MR study was performed using the inverse variance weighted as the main method. The heterogeneity, horizontal pleiotropy, MR Steiger, and leave-one-out analyses were also conducted as sensitivity tests.ResultsThere was indicative evidence that genetically predicted low-density lipoprotein cholesterol (LDL-C) affected bladder cancer susceptibility based on 146 single nucleotide polymorphisms (SNPs) with an odds ratio (OR) of 0.776 (95% confidence interval [CI] = 0.625–0.965, p = 0.022). However, this result became non-significant after two SNPs that possibly drove the effect were removed as demonstrated by leave-one-out analysis. The reversed MR analysis suggested that bladder cancer could not affect serum lipid levels. No causal relationship was found between the lipid-lowering effect of lipid-regulatory medications (fibrates, probucol, statins, ezetimibe, proprotein convertase subtilisin/kexin type 9 [PCSK9] inhibitors, and evinacumab) and the risk of bladder cancer. No heterogeneity or pleiotropy was found (all p > 0.05).ConclusionThis MR study revealed for the first time, using the most recent and comprehensive GWAS data to date, that genetically predicted total cholesterol (TC) and the lipid-lowering effect of lipid-regulatory medications had no causal association with bladder cancer susceptibility. We also verified claims from early studies that low-density lipoprotein cholesterol (HDL-C), LDL-C, and triglyceride (TG) are not related to bladder cancer susceptibility either. The current study indicated that lipid metabolism may not be as important in the tumorigenesis of bladder cancer as previously believed.

Keywords